124 related articles for article (PubMed ID: 2863295)
1. Hemodynamic effects of an oral dopamine receptor agonist (fenoldopam) in patients with congestive heart failure.
Young JB; Leon CA; Pratt CM; Suarez JM; Aronoff RD; Roberts R
J Am Coll Cardiol; 1985 Oct; 6(4):792-6. PubMed ID: 2863295
[TBL] [Abstract][Full Text] [Related]
2. Hemodynamic, renal, and neurohumoral effects of a selective oral DA1 receptor agonist (fenoldopam) in patients with congestive heart failure.
Francis GS; Wilson BC; Rector TS
Am Heart J; 1988 Aug; 116(2 Pt 1):473-9. PubMed ID: 2899970
[TBL] [Abstract][Full Text] [Related]
3. Intravenous fenoldopam in heart failure: comparing the hemodynamic effects of dopamine1 receptor agonism with nitroprusside.
Young JB; Leon CA; Pratt CM; Kingry C; Taylor AA; Roberts R
Am Heart J; 1988 Feb; 115(2):378-84. PubMed ID: 2893527
[TBL] [Abstract][Full Text] [Related]
4. Beneficial effects of fenoldopam on systemic and regional hemodynamics in rabbits with congestive heart failure.
Jover BF; McGrath BP
J Cardiovasc Pharmacol; 1988 Apr; 11(4):483-8. PubMed ID: 2453754
[TBL] [Abstract][Full Text] [Related]
5. Immediate hemodynamic effects of a dopamine-receptor agonist (fenoldopam) in patients with essential hypertension.
Ventura HO; Messerli FH; Frohlich ED; Kobrin I; Oigman W; Dunn FG; Carey RM
Circulation; 1984 Jun; 69(6):1142-5. PubMed ID: 6143625
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic effects of a new inotropic agent, piroximone (MDL 19205), in patients with chronic heart failure.
Petein M; Levine TB; Cohn JN
J Am Coll Cardiol; 1984 Aug; 4(2):364-71. PubMed ID: 6736478
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary and systemic vascular effects of SKF-82526-J, a new specific peripheral dopamine receptor agonist, in unanesthetized neonatal lambs.
Drummond WH; Williams BJ; Kelley KC
Dev Pharmacol Ther; 1983; 6(1):1-8. PubMed ID: 6132785
[TBL] [Abstract][Full Text] [Related]
8. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.
Carey RM; Stote RM; Dubb JW; Townsend LH; Rose CE; Kaiser DL
J Clin Invest; 1984 Dec; 74(6):2198-207. PubMed ID: 6150942
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the renal and pulmonary hemodynamic effects of fenoldopam, dobutamine, dopamine and norepinephrine in the anesthetized dog.
Shebuski RJ; Smith JM; Ruffolo RR
Pharmacology; 1988; 36(1):35-43. PubMed ID: 2893393
[TBL] [Abstract][Full Text] [Related]
10. Assessment of hemodynamic tolerance from a 24-hour intravenous infusion of fenoldopam mesylate in congestive heart failure.
Munger MA; Benotti JR; Green JA; Jarvis RC; Nara AR; McCue JE; Pospisil RA; Kasmer RJ
Am J Cardiol; 1990 Jan; 65(3):206-10. PubMed ID: 1967511
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.
Glück Z; Jossen L; Weidmann P; Gnädinger MP; Peheim E
Hypertension; 1987 Jul; 10(1):43-54. PubMed ID: 2885268
[TBL] [Abstract][Full Text] [Related]
12. The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
Blanchett DG; Green JA; Nara A; Pospisil R; Jarvis RC; Kasmer RJ; Boyle DA; Cyronak MJ; Corder CN
Clin Pharmacol Ther; 1991 Apr; 49(4):449-56. PubMed ID: 1673097
[TBL] [Abstract][Full Text] [Related]
13. The effects of fenoldopam, a selective dopamine receptor agonist, on systemic and renal hemodynamics in normotensive subjects.
Mathur VS; Swan SK; Lambrecht LJ; Anjum S; Fellmann J; McGuire D; Epstein M; Luther RR
Crit Care Med; 1999 Sep; 27(9):1832-7. PubMed ID: 10507606
[TBL] [Abstract][Full Text] [Related]
14. Systemic and coronary hemodynamic and neurohumoral effects of levodopa in chronic congestive heart failure.
De Marco T; Daly PA; Chatterjee K
Am J Cardiol; 1988 Dec; 62(17):1228-33. PubMed ID: 2904216
[TBL] [Abstract][Full Text] [Related]
15. Acute hemodynamic effect of oral nifedipine in severe chronic congestive heart failure.
Elkayam U; Weber L; Torkan B; Berman D; Rahimtoola SH
Am J Cardiol; 1983 Nov; 52(8):1041-5. PubMed ID: 6637820
[TBL] [Abstract][Full Text] [Related]
16. Hemodynamic and neurohumoral effects of long-term prostaglandin E1 infusions in outpatients with severe congestive heart failure.
Hülsmann M; Stanek B; Frey B; Berger R; Rödler S; Siegel A; Hartter E; Schuller M; Ogris E; Pacher R
J Heart Lung Transplant; 1997 May; 16(5):556-62. PubMed ID: 9171275
[TBL] [Abstract][Full Text] [Related]
17. Evidence against a role for dopamine D1 receptors in the myocardium of the pig.
Van Woerkens LJ; Duncker DJ; Den Boer MO; McFalls EO; Sassen LM; Saxena PR; Verdouw PD
Br J Pharmacol; 1991 Sep; 104(1):246-50. PubMed ID: 1686206
[TBL] [Abstract][Full Text] [Related]
18. Selective dopamine-1 agonist therapy in severe hypertension: effects of intravenous fenoldopam.
White WB; Radford MJ; Gonzalez FM; Weed SG; McCabe EJ; Katz AM
J Am Coll Cardiol; 1988 May; 11(5):1118-23. PubMed ID: 2895780
[TBL] [Abstract][Full Text] [Related]
19. Beneficial hemodynamic effects of intravenous and oral diltiazem in severe congestive heart failure.
Walsh RW; Porter CB; Starling MR; O'Rourke RA
J Am Coll Cardiol; 1984 Apr; 3(4):1044-50. PubMed ID: 6707341
[TBL] [Abstract][Full Text] [Related]
20. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure.
Insel J; Mirvis DM; Boland MJ; Cinquegrani MP; Shanes J; Rubin SA; Whalen JJ
Clin Pharmacol Ther; 1989 Mar; 45(3):312-20. PubMed ID: 2537699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
